New osteoporosis drug could offer cheaper alternative to prolia

NCT ID NCT05345691

Completed Disease control Sponsor: Biocon Biologics UK Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether a biosimilar called Bmab 1000 works as well as the established drug Prolia® for treating osteoporosis in postmenopausal women. 479 women aged 55-79 with osteoporosis received either Bmab 1000 or Prolia® as an injection every 6 months. The study measured changes in bone density and bone turnover markers to see if the two drugs are equivalent.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bmab 1000 (a biosimilar of denosumab, given as an injection every 6 months)
What this could lead to: If successful, this could provide a more affordable treatment option for osteoporosis, helping to prevent fractures in postmenopausal women.
What could go wrong: This is a biosimilar comparison trial, not a new breakthrough. Even if it works, it may not offer any advantage over the existing drug, and long-term safety data are still limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

Contacts and locations

Locations

PPD Global Ltd, Granta Park, Great Abington,

Cambridge, UK, CB21 6GQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.